These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35809119)

  • 1. Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study.
    Best MC; Bartley N; Napier CE; Fisher A; Ballinger ML; Thomas DM; Goldstein D; Tucker K; Biesecker BB; Butow P
    Support Care Cancer; 2022 Oct; 30(10):8201-8210. PubMed ID: 35809119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling.
    Best M; Newson AJ; Meiser B; Juraskova I; Goldstein D; Tucker K; Ballinger ML; Hess D; Schlub TE; Biesecker B; Vines R; Vines K; Thomas D; Young MA; Savard J; Jacobs C; Butow P
    BMC Cancer; 2018 Apr; 18(1):389. PubMed ID: 29621994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results.
    Vatter S; Schlub TE; Napier CE; Best MC; Bartley N; Juraskova I; Meiser B; Ballinger ML; Biesecker BB; Goldstein D; Thomas DM; Butow P;
    Health Psychol; 2022 Jun; 41(6):396-408. PubMed ID: 35604703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients.
    Butow PN; Best MC; Davies G; Schlub T; Napier CE; Bartley N; Ballinger ML; Juraskova I; Meiser B; Goldstein D; Biesecker B; Thomas DM;
    Patient Educ Couns; 2022 Jul; 105(7):2206-2216. PubMed ID: 35153126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study.
    Matsuoka A; Fujimori M; Koyama T; Sato A; Mori K; Hirata M; Tanabe N; Nakachi K; Kato S; Okamoto H; Ogawa K; Komatsu H; Iwasaku M; Miyaji T; Uchitomi Y
    BMJ Open; 2023 Nov; 13(11):e072472. PubMed ID: 37996226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients.
    Bartley N; Best MC; Biesecker BB; Fisher A; Goldstein D; Meiser B; Thomas DM; Ballinger ML; Butow P
    Patient Educ Couns; 2022 Feb; 105(2):452-459. PubMed ID: 34016496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis.
    Sivakumar S; Lee JK; Moore JA; Hopkins J; Newberg JY; Madison R; Graf R; Schrock AB; Kobetz E; Vince R; Franco I; Seldon C; Frampton GM; Mills J; Venstrom J; Mahal BA
    Lancet Digit Health; 2023 Jun; 5(6):e380-e389. PubMed ID: 37236698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of psychological distress, quality of life, and satisfaction among patients and family members following comprehensive genomic profiling testing: Protocol of the Quality of life for Cancer genomics and Advanced Therapeutics (Q-CAT) study.
    Nishino M; Fujimori M; Koyama T; Hirata M; Tanabe N; Shimizu T; Yamamoto N; Uchitomi Y
    PLoS One; 2023; 18(5):e0283968. PubMed ID: 37235572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies.
    Matsuo M; Hashimoto K; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
    In Vivo; 2023; 37(5):2147-2154. PubMed ID: 37652518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of barriers to implementation of precision oncology in patients with rare cancers.
    Takamizawa S; Koyama T; Sunami K; Sudo K; Hirata M; Kubo T; Tao K; Cho H; Narita Y; Kato K; Yamazaki N; Ohe Y; Okusaka T; Matsui Y; Ogawa C; Yonemori K; Yamamoto N
    Cancer Sci; 2024 Jun; 115(6):2023-2035. PubMed ID: 38538548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
    Tomlins SA; Hovelson DH; Suga JM; Anderson DM; Koh HA; Dees EC; McNulty B; Burkard ME; Guarino M; Khatri J; Safa MM; Matrana MR; Yang ES; Menter AR; Parsons BM; Slim JN; Thompson MA; Hwang L; Edenfield WJ; Nair S; Onitilo A; Siegel R; Miller A; Wassenaar T; Irvin WJ; Schulz W; Padmanabhan A; Harish V; Gonzalez A; Mansoor AH; Kellum A; Harms P; Drewery S; Falkner J; Fischer A; Hipp J; Kwiatkowski K; Lazo de la Vega L; Mitchell K; Reeder T; Siddiqui J; Vakil H; Johnson DB; Rhodes DR
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
    Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
    J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm.
    O'Haire S; Degeling K; Franchini F; Tran B; Luen SJ; Gaff C; Smith K; Fox S; Desai J; IJzerman M
    Target Oncol; 2022 Sep; 17(5):539-548. PubMed ID: 36063280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
    Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
    Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethical frameworks for obtaining informed consent in tumour profiling: an evidence-based case for Singapore.
    Bylstra Y; Lysaght T; Thrivikraman J; Watson S; Tan P
    Hum Genomics; 2017 Dec; 11(1):31. PubMed ID: 29221462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer.
    Tjota MY; Segal JP; Wang P
    J Appl Lab Med; 2024 Jan; 9(1):76-91. PubMed ID: 38167763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.